RxDoctor Payments Data

Michael Mikolaj, MD

Cardiovascular Disease · Chattanooga, TNNPI 1760616601

Payments from drug & device makers

$6,229in general payments, 2019–2025

Across 194 payments — averaging $32.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$3K
  • Novartis$832
  • Pfizer$512
  • Lantheus Medical Imaging, Inc.$193
  • E.r. Squibb & Sons, L.L.C.$186
  • Boston Scientific$169
  • plus $2K from 31 others

What the payments were for

  • Consulting fees$2,52741%
  • Food & beverage$3,70259%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,229 in reported general payments places this provider in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$132,116
Medicare patients
1,604
Services billed
2,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis11$257,938
JardianceEmpagliflozin96$84,864
EliquisApixaban94$84,097
EntrestoSacubitril/Valsartan82$78,595
FarxigaDapagliflozin Propanediol71$65,288
XareltoRivaroxaban41$37,671
Repatha SureclickEvolocumab22$12,011
Metoprolol Succinate139$1,769
Spironolactone150$1,488
Atorvastatin Calcium166$1,363
Ranolazine ErRanolazine12$1,192
Carvedilol104$685
Lisinopril102$631
Valsartan15$586
ClopidogrelClopidogrel Bisulfate57$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$512$342,035105 claims
Boehringer IngelheimJardiance$165$84,86496 claims
NovartisEntresto$832$78,59582 claims
AstraZenecaFarxiga$12$65,28871 claims
Johnson & JohnsonXarelto$146$37,67141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →